PREDAMIDE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for PREDAMIDE (PREDAMIDE).
Predamide (a combination of prednisolone and sulfadimethoxine) exerts its effects via the corticosteroid anti-inflammatory action of prednisolone (inhibition of phospholipase A2, reduced prostaglandin synthesis) and the bacteriostatic action of sulfadimethoxine (competitive antagonism of para-aminobenzoic acid, inhibiting dihydropteroate synthase in folate synthesis).
| Metabolism | Prednisolone is primarily metabolized in the liver via 11β-hydroxysteroid dehydrogenase and cytochrome P450 3A4 (CYP3A4). Sulfadimethoxine is metabolized in the liver via acetylation and glucuronidation. |
| Excretion | Renal (80% as unchanged drug and metabolites, primarily glucuronide and sulfate conjugates), biliary/fecal (20%). |
| Half-life | Terminal elimination half-life: 12-15 hours. In hepatic impairment, half-life may extend to 20-25 hours; in renal impairment (CrCl <30 mL/min), half-life increases to 30-40 hours. |
| Protein binding | 98-99% bound primarily to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | 0.2-0.4 L/kg (approximately 14-28 L in a 70 kg adult), indicating distribution primarily in extracellular fluid. |
| Bioavailability | Oral: 75-85% (first-pass metabolism reduces bioavailability; food may decrease rate but not extent). |
| Onset of Action | Oral: 30-60 minutes. Intravenous: 5-10 minutes. |
| Duration of Action | Oral: 6-12 hours. Intravenous: 6-12 hours. Duration may be prolonged in hepatic or renal impairment. |
| Molecular Weight | 358.48 |
Prednisone 5 mg orally once daily, adjusted based on response.
| Dosage form | SUSPENSION/DROPS |
| Renal impairment | No specific GFR-based dose adjustments; use with caution in severe renal impairment. |
| Liver impairment | No formal Child-Pugh recommendations; avoid in severe hepatic impairment due to increased risk of toxicity. |
| Pediatric use | Weight-based dosing: 0.1-0.2 mg/kg/day orally up to a maximum of 5 mg/day. |
| Geriatric use | Initiate at lowest effective dose (e.g., 2.5 mg/day) and titrate slowly due to increased risk of adverse effects. |
| 1st trimester | Prednisone crosses the placenta. Use only if clearly needed. Monitor for orofacial clefts (small increased risk). |
| 2nd trimester | Use with caution. May cause fetal adrenal suppression if prolonged high doses. Monitor fetal growth. |
| 3rd trimester | Use with caution. Risk of neonatal adrenal suppression if used near term. Wean if possible. |
Clinical note
Comprehensive clinical and safety monograph for PREDAMIDE (PREDAMIDE).
| Placental transfer | Prednisone is partially metabolized to prednisolone in the placenta; fetal levels are about 10% of maternal serum levels. |
| Breastfeeding | Prednisone is excreted into breast milk in low amounts (less than 10% of maternal dose). Doses up to 40 mg daily are considered compatible with breastfeeding. Monitor infant for potential adrenal suppression and growth. |
■ FDA Black Box Warning
WARNING: Sulfadimethoxine may cause severe hypersensitivity reactions including Stevens-Johnson syndrome, toxic epidermal necrolysis, and agranulocytosis. Corticosteroids may mask signs of infection and increase susceptibility to secondary infections.
| Serious Effects |
Systemic fungal infectionHypersensitivity to prednisone or any component
| Precautions | May exacerbate infections; avoid live vaccines. Prolonged corticosteroid use may lead to adrenal suppression, osteoporosis, and immunosuppression. Sulfadimethoxine may cause crystalluria, hemolytic anemia in G6PD deficiency, and photosensitivity. |
| Food/Dietary | No clinically significant food interactions. Systemic absorption is minimal with ophthalmic use. No dietary restrictions required. |
Loading safety data…
| Lactation Rating |
| L2 |
| Teratogenic Risk | Predamide is a fixed-dose combination of prednisolone and salicylamide. Prednisolone is a corticosteroid. First trimester: increased risk of cleft palate (odds ratio 3.4). Second/third trimester: fetal adrenal suppression, intrauterine growth restriction, premature rupture of membranes. Salicylamide: potential for premature closure of ductus arteriosus (third trimester), oligohydramnios, neonatal hemorrhage. |
| Fetal Monitoring | Monitor maternal blood pressure, blood glucose, fetal growth (ultrasound every 4 weeks after 24 weeks), amniotic fluid volume, fetal heart rate. Avoid use after 32 weeks due to ductus arteriosus closure risk. |
| Fertility Effects | Prednisolone may suppress ovulation and menstrual regularity; salicylamide no known direct effect. Both may impair male fertility in animal studies, but human data limited. |
| Clinical Pearls | Predamide (Prednisolone + Sulfacetamide) is an ophthalmic suspension combining a corticosteroid and antibiotic. Use with caution in patients with glaucoma; monitor intraocular pressure. Avoid prolonged use due to risk of secondary infections, cataract formation, and corneal perforation in patients with corneal thinning. Do not use in viral or fungal eye infections. Shake well before each use. Discard after 30 days of opening. |
| Patient Advice | Shake the bottle vigorously before each use to ensure uniform suspension. · Wash hands before applying and avoid touching the dropper tip to any surface. · Do not wear contact lenses during treatment unless directed by your doctor. · Use exactly as prescribed; do not stop early even if symptoms improve. · Report any eye pain, vision changes, or worsening redness immediately. |